Literature DB >> 24634493

Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Martin Felices1, Todd R Lenvik, Dave E M Ankarlo, Bree Foley, Julie Curtsinger, Xianghua Luo, Bruce R Blazar, Stephen K Anderson, Jeffrey S Miller.   

Abstract

Acquisition of a functional NK cell repertoire, known as education or licensing, is a complex process mediated through inhibitory receptors that recognize self. We found that NK cells containing self-killer Ig-like receptors for cognate HLA ligand in vivo were less susceptible to apoptosis. In vitro IL-15 withdrawal showed that uneducated NK cells upregulated Bim and Fas. Conversely, educated NK cells upregulated Fas ligand (FasL) under these conditions. Induction of cell death and Bim expression on uneducated cells correlated with increased IL-2Rα expression. Overexpression and knockdown studies showed that higher IL-2Rα limits NK cell survival in a novel manner that is independent from the role of IL-2 in activation-induced cell death. To study the role of FasL in induction of IL-2Rα(hi) NK cell death, a coculture assay with FasL-blocking Abs was used. IL-15 withdrawal led to FasL-dependent killing of IL-2Rα(hi) NK cells by more educated IL-2Rα(lo) NK cells. Finally, CMV reactivation induces a potent long-lasting population of licensed NK cells with enhanced survival. These findings show that education-dependent NK cell survival advantages and killing of uneducated NK cells result in the maintenance of a functional repertoire, which may be manipulated to exploit NK cells for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634493      PMCID: PMC3979985          DOI: 10.4049/jimmunol.1302601

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets.

Authors:  Petter Brodin; Tadepally Lakshmikanth; Klas Kärre; Petter Höglund
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 2.  NK cell MHC class I specific receptors (KIR): from biology to clinical intervention.

Authors:  Ariane Thielens; Eric Vivier; François Romagné
Journal:  Curr Opin Immunol       Date:  2012-01-20       Impact factor: 7.486

Review 3.  NK cells--from bench to clinic.

Authors:  William J Murphy; Peter Parham; Jeffrey S Miller
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

4.  Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.

Authors:  Cristina Bergamaschi; Jenifer Bear; Margherita Rosati; Rachel Kelly Beach; Candido Alicea; Raymond Sowder; Elena Chertova; Steven A Rosenberg; Barbara K Felber; George N Pavlakis
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

5.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

6.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

7.  Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Julie Curtsinger; Xianghua Luo; Edmund K Waller; Claudio Anasetti; Daniel Weisdorf; Jeffrey S Miller
Journal:  J Immunol       Date:  2012-10-17       Impact factor: 5.422

8.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Authors:  S Ito; P Pophali; Wu CO; E K Koklanaris; J Superata; G A Fahle; R Childs; M Battiwalla; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2013-04-08       Impact factor: 5.483

9.  LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase.

Authors:  F Marti; C W Xu; A Selvakumar; R Brent; B Dupont; P D King
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15.

Authors:  Aaron M Ring; Jian-Xin Lin; Dan Feng; Suman Mitra; Mathias Rickert; Gregory R Bowman; Vijay S Pande; Peng Li; Ignacio Moraga; Rosanne Spolski; Engin Ozkan; Warren J Leonard; K Christopher Garcia
Journal:  Nat Immunol       Date:  2012-10-28       Impact factor: 25.606

View more
  12 in total

Review 1.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

2.  Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.

Authors:  Letizia Muccio; Alice Bertaina; Michela Falco; Daniela Pende; Raffaella Meazza; Miguel Lopez-Botet; Lorenzo Moretta; Franco Locatelli; Alessandro Moretta; Mariella Della Chiesa
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 3.  T Regulatory Cell Biology in Health and Disease.

Authors:  Fayhan J Alroqi; Talal A Chatila
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

4.  NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's disease patients.

Authors:  Susy Yusung; Dermot McGovern; Lin Lin; Daniel Hommes; Venu Lagishetty; Jonathan Braun
Journal:  Clin Immunol       Date:  2016-12-21       Impact factor: 10.190

5.  A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Authors:  Juliane Wagner; Viktoria Pfannenstiel; Anja Waldmann; Judith W J Bergs; Boris Brill; Sabine Huenecke; Thomas Klingebiel; Franz Rödel; Christian J Buchholz; Winfried S Wels; Peter Bader; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-06-12       Impact factor: 7.561

Review 6.  Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection.

Authors:  Angelique Hölzemer; Wilfredo F Garcia-Beltran; Marcus Altfeld
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

7.  Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity.

Authors:  Arnika K Wagner; Ulf Gehrmann; Stefanie Hiltbrunner; Valentina Carannante; Thuy T Luu; Tanja I Näslund; Hanna Brauner; Nadir Kadri; Klas Kärre; Susanne Gabrielsson
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

8.  Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients.

Authors:  Vivien Béziat; Marwan Sleiman; Jodie P Goodridge; Mari Kaarbø; Lisa L Liu; Halvor Rollag; Hans-Gustaf Ljunggren; Jacques Zimmer; Karl-Johan Malmberg
Journal:  Front Immunol       Date:  2015-10-06       Impact factor: 7.561

Review 9.  Newtonian cell interactions shape natural killer cell education.

Authors:  Jodie P Goodridge; Björn Önfelt; Karl-Johan Malmberg
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

10.  Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma.

Authors:  Azuchi Masuda; Yasushi Isobe; Koichi Sugimoto; Mayumi Yoshimori; Ayako Arai; Norio Komatsu
Journal:  Cancer Sci       Date:  2020-01-31       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.